natgillin/translations-raw huggingface dataset:
Patients currently treated with an ESA:
Bolesnici koji se trenutno liječe lijekovima za stimulaciju eritropoeze (LSE):
Patients demonstrating a Pediatric ACR 30 response at Week 16 were eligible to be randomised into the double blind (DB) phase and received either Humira 24 mg/m2 up to a maximum of 40 mg, or placebo every other week for an additional 32 weeks or until disease flare.
Bolesnici koji su u 16. tjednu pokazali pedijatrijski odgovor ACR 30 (American College of Rheumatology 30) mogli su biti randomizirani u dvostruko slijepu fazu ispitivanja i primiti ili 24 mg/m2 lijeka Humira, do maksimalne doze od 40 mg, ili placebo, svaki drugi tjedan kroz 32 tjedna ili do ponovne reaktivacije bolesti.
Patients demonstrating a subsequent increase in QT-interval to > 480 msec or prolongation over pre-treatment by > 20 msec should discontinue ritonavir-boosted Invirase.
Bolesnici u kojih se utvrdi naknadno produljenje QT-intervala na > 480 ms ili produljenje u odnosu na početne vrijednosti za > 20 ms trebaju prestati uzimati Invirase pojačan ritonavirom.
Patients designated as YMDD mutant were those with 5% YMDD mutant HBV at any annual time-point during the 5-year period.
Bolesnici s YMDD mutiranim tipom virusa definirani su kao oni ≥5 % YMDD mutiranog HBV na barem jednom od godišnjih mjerenja tijekom petogodišnjeg razdoblja.
Patients developing Factor VIII inhibitors
Bolesnici u kojih su se razvili inhibitori faktora VIII
Patients developing inhibitory antibodies to OBIZUR
Bolesnici koji razviju inhibicijska protutijela na OBIZUR
Patients diagnosed with hepatic impairment while receiving Jakavi should have complete blood counts, including a white blood cell count differential, monitored at least every one to two weeks for the first 6 weeks after initiation of therapy with Jakavi and as clinically indicated thereafter once their liver function and blood counts have been stabilised.
Bolesnicima kojima je dijagnosticirano oštećenje jetre dok uzimaju Jakavi treba pratiti kompletnu krvnu sliku, uključujući i diferencijalnu krvnu sliku leukocita, najmanje svakih tjedan do dva tijekom prvih 6 tjedana od uvođenja terapije Jakavijem te u skladu s kliničkim indikacijama nakon što im se funkcija jetre i krvna slika stabiliziraju.
patients diagnosed with or being treated for cancer;
bolesnicima kojima je dijagnosticiran ili koji se liječe od raka;
Patients diagnosed with pulmonary hypertension, in particular, should receive adequate doses of Cerezyme to ensure control of underlying Gaucher disease as well as be evaluated for the need of additional pulmonary hypertension specific treatments.
Posebno je važno da bolesnici kojima je dijagnosticirana plućna hipertenzija dobiju odgovarajuću dozu lijeka Cerezyme kako bi se osigurala kontrola osnovne Gaucherove bolesti kao i procijenila potreba za dodatnim specifičnim lijekovima za plućnu hipertenziju.
Patients diagnosed with relapsing multiple sclerosis (MS).
bolesnika s dijagnozom relapsne multiple skleroze (MS).
Patients either changed to Atripla (N=203) or continued on their original antiretroviral treatment regimen (N=97).
Pacijenti su ili prešli na Atriplu (N=203) ili su nastavili sa svojim prvotnim režimom antiretrovirusnog liječenja (N=97).
Patients eligible for fondaparinux 2.5 mg treatment should have acute, symptomatic, isolated, spontaneous superficial-vein thrombosis of the lower limbs, at least 5 cm long and documented by ultrasonographic investigation or other objective methods.
Bolesnici kojima je indicirana primjena fondaparinuksa od 2,5 mg su bolesnici s akutnom, simptomatskom, izoliranom, spontanom trombozom površinske vene donjih ekstremiteta, koji zahvaća venu u dužini od barem 5 cm, a potvrđen je ultrazvukom ili nekom drugom objektivnom metodom.
Patients eligible for stem cell transplantation
Bolesnici kod kojih je transplantacija matičnih stanica prikladna
Patients enrolled had IPAH or PAH associated with connective tissue disease (PAH-CTD).
Uključeni bolesnici su bolovali od IPAH- a ili PAH-a povezanog s bolešću vezivnog tkiva (PAH-CTD).
Patients enrolled into ARIES-1 and 2 were eligible to enter a long term open label extension study ARIES-E (n=383).
Bolesnici uključeni u ARIES-1 i 2 su mogli biti uključeni u dugoročno otvoreno, produženo ispitivanje ARIES E (n=383).
Patients enrolled into ARIES-1 and 2 were eligible to enter a long term open label extension study ARIES-E (n=383).
Bolesnici uključeni u ARIES-1 i 2 su mogli biti uključeni u dugoročno otvoreno, produženo ispitivanje ARIES-E (n=383).
Patients enrolled into the epoprostenol add-on therapy study were eligible to enter a long term open label extension study.
Bolesnici uključeni u ispitivanje dodatnog liječenja epoprostenolom bili su pogodni za ulazak u dugotrajan produžetak otvorenog ispitivanja.
Patients enrolled into the epoprostenol add-on therapy study were eligible to enter a long term open label extension study.
Bolesnici uključeni u ispitivanje dodatnog liječenja epoprostenolom bili su pogodni za ulazak u dugotrajan produžetak otvornog ispitivanja.
Patients enrolled into the pivotal oral route study were eligible to enter a long term open label extension study.
Bolesnici uključeni u pivotalno ispitivanje s peroralnom primjenom lijeka bili su pogodni za ulazak u dugotrajan produžetak otvorenog ispitivanja.
patients exhibited withdrawal
U oba su ispitivanja
Patients exhibiting depression should be monitored closely during therapy and treated appropriately.
Bolesnike koji pokazuju simptome depresije , treba pomno nadzirati tijekom liječenja i primjereno liječiti.
Patients exhibiting signs and symptoms of AMS should receive a thorough neurological examination, including CSF studies, to rule out other causes of meningitis.
U bolesnika koji pokazuju znakove i simptome AMS-a moraju se provesti temeljite neurološke pretrage, uključujući i CSF ispitivanja, kako bi se isključili drugi uzroci meningitisa.
Patients experiencing a laryngeal attack should always seek medical advice and be observed in a medical institution also after having taken the injection at home.
Bolesnici koji dožive laringealni napadaj trebali bi uvijek potražiti liječnički savjet i otići na promatranje u zdravstvenu ustanovu i nakon primjene injekcije kod kuće.
Patients experiencing anaemia during or after treatment with Zavicefta should be investigated for this possibility.
Tu mogućnost treba ispitati kod bolesnika koji razviju anemiju tijekom ili nakon liječenja lijekom Zavicefta.
Patients experiencing dizziness while taking Orkambi should be advised not to drive or use machines until symptoms abate.
Bolesnicima koji osjete omaglicu dok uzimaju Orkambi mora se savjetovati da ne upravljaju vozilima i strojevima dok ti simptomi traju.
Patients experiencing dizziness, fatigue, visual impairment or other undesirable effects with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects persist (see section 4.8).
Bolesnici s omaglicom, umorom, poremećajima vida ili drugim nuspojavama koje mogu utjecati na sposobnost sigurnog upravljanja vozilom ili rada na strojevima trebaju prestati s tim aktivnostima sve dok traju nuspojave (vidjeti dio 4.8).
Patients experiencing dyspnoea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of a fatal ARR.
Bolesnici s dispnejom u mirovanju uslijed komplikacija uznapredovale zloćudne bolesti i popratnih komorbiditeta, mogu imati povećan rizik od smrtonosnih reakcija povezanih s primjenom lijeka.
Patients experiencing infusion-related reactions should be advised not to drive and use machines until symptoms abate.
Bolesnicima u kojih se pojave reakcije povezane s infuzijom mora se savjetovati da ne upravljaju vozilima i ne rade sa strojevima dok se simptomi ne povuku.
Patients experiencing mild or moderate infusion-associated reactions when treated with agalsidase beta during clinical trials have continued therapy after a reduction in the infusion rate (~0.15 mg/min; 10 mg/hr) and/or pre-treatment with antihistamines, paracetamol, ibuprofen and/or corticosteroids.
Bolesnici koji su doživjeli blage do umjerene reakcije povezane s infuzijom tijekom liječenja agalzidazom beta u sklopu kliničkih ispitivanja nastavili su liječenje nakon smanjenja brzine infuzije (~0,15 mg/min; 10 mg/sat) i/ili prethodne primjene antihistaminika, paracetamola, ibuprofena i/ili kortikosteroida.
Patients experiencing new or worsening peripheral neuropathy should undergo neurological evaluation and may require a change in the dose or schedule of VELCADE (see section 4.2).
Bolesnike kod kojih se pojavi nova ili im se pogorša postojeća periferna neuropatija mora se neurološki pregledati, a po potrebi im treba promijeniti dozu ili vremenski raspored primjene VELCADEa (vidjeti dio 4.2).
Patients experiencing new or worsening peripheral neuropathy should undergo neurological evaluation and may require a change in the dose, schedule or route of administration to subcutaneous (see section 4.2).
Bolesnike kod kojih se pojavi nova ili im se pogorša postojeća periferna neuropatija mora se neurološki pregledati, a po potrebi im treba promijeniti dozu ili vremenski raspored primjene ili promijeniti put primjene na supkutani (vidjeti dio 4.2).
Patients experiencing pain during and after patch application should be provided with supportive treatment such as local cooling or oral analgesics (i.e. short acting opioids).
Bolesnici koji osjećaju bol tijekom i nakon stavljanja flastera trebali bi dobiti suportivno liječenje kao što su lokalno hlađenje ili peroralni analgetici (tj. kratko djelujući opioidi).
Patients experiencing rash during the 14-day lead-in period of 200 mg/day should not have their Nevirapine Teva dose increased until the rash has resolved.
Bolesnicima kod kojih se tijekom 14-dnevnog uvodnog razdoblja uz dozu od 200 mg/dan pojavi osip ne smiju povećavati dozu Nevirapina Teva dok se osip ne povuče.
Patients experiencing rash during the 14-day lead-in period of 200 mg/day should not initiate treatment with Viramune prolonged-release tablets until the rash has resolved.
Bolesnici koji razviju osip tijekom 14-dnevnog uvodnog razdoblja ne smiju počinjati liječenje Viramune tabletama s produljenim oslobađanjem dok se osip ne riješi.
Patients experiencing skin reactions should be encouraged to avoid exposure to sunlight and apply broad spectrum sunscreens with a Sun Protection Factor (SPF)  30.
Bolesnike koji imaju kožne reakcije treba savjetovati da izbjegavaju izlaganje sunčevom svjetlu te da koriste zaštitne kreme širokog spektra sa zaštitnim faktorom ≥30.
Patients experiencing these adverse reactions should not drive or use machines.
Bolesnici u kojih se pojave te nuspojave ne bi trebali upravljati vozilima ni raditi sa strojevima.
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p<0.0001 for all).
Bolesnici izloženi Plegridyju svaka 2 tjedna pokazali su statistički značajna smanjenja u odnosu na bolesnike koji su bili izloženi Plegridyju svaka 4 tjedna tijekom 2 godine u post-hoc analizi ishoda uključujući ARR (24%, p=0,0209), rizik od relapsa (24%, p=0,0212), rizik od progresije onesposobljenosti potvrđen u 24. tjednu (36%, p = 0,0459), i MR ishode (nove/povećane T2 60%, Gd+ 71%, i nove T1 hipointenzivne lezije 53%; p <0,0001 za sve.)
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p<0.0001 for all).
Bolesnici izloženi Plegridyju svaka 2 tjedna pokazali su statistički značajna smanjenja u odnosu na bolesnike koji su bili izloženi Plegridyju svaka 4 tjedna tijekom 2 godine u post-hoc analizi ishoda uključujući ARR (24%, p=0,0209), rizik od relapsa (24%, p=0,0212), rizik od progresije onesposobljenosti potvrđen u 24. tjednu (36%, p = 0,0459), i MR ishode (nove/povećanje T2 60%, Gd+ 71%, i nove T1 hipointenzivne lezije 53%; p <0,0001 za sve.)
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p<0.0001 for all).
Bolesnici izloženi Plegridyju svaka 2 tjedna pokazali su statistički značajna smanjenja u odnosu na bolesnike koji su bili izloženi Plegridyju svaka 4 tjedna tijekom 2 godine u post-hoc analizi ishoda uključujući ARR (24%, p=0,0209), rizik od relapsa (24%, p=0,0212), rizik od progresije onesposobljenosti potvrđen u 24. tjednu (36%, p = 0,0459), i MR ishode (nove/uvećane T2 60%, Gd+ 71%, i nove T1 hipointenzivne lezije 53%; p <0,0001 za sve.)
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p<0.0001 for all).
Bolesnici izloženi Plegridyju svaka 2 tjedna pokazali su statistički značajna smanjenja u odnosu na bolesnike koji su bili izloženi Plegridyju svaka 4 tjedna tijekom 2 godine u post-hoc analizi ishoda uključujući ARR (24%, p=0,0209), rizik od relapsa (24%, p=0,0212), rizik od progresije onesposobljenosti potvrđenu 24. tjednu (36%, p = 0,0459), i MR ishode (nove/povećane T2 60%, Gd+ 71%, i nove T1 hipointenzivne lezije 53%; p <0,0001 za sve.)
Patients following elective knee replacement surgery
Bolesnici nakon elektivnog kirurškog zahvata ugradnje endoproteze koljena
patients for clinical effects.
nadzor bolesnika za
patients from 2 years of age with beta thalassaemia major who receive infrequent blood transfusions, when deferoxamine cannot be used or is inadequate; patients from 2 years of age who suffer from other types of anaemia (low levels of haemoglobin in the blood) who receive blood transfusions, when deferoxamine cannot be used or is inadequate;
u bolesnika u dobi od 2 godine i starijih s beta-talasemijom major i neučestalim transfuzijama krvi u slučaju kada se deferoksamin ne može primjenjivati ili kada njegova primjena nije prikladna; u bolesnika u dobi od 2 godine i starijih s drugim vrstama anemije (niskim razinama hemoglobina u krvi) koji primaju transfuziju krvi, u slučaju kada se deferoksamin ne može primjenjivati ili kada njegova primjena nije prikladna;
patients from 6 years of age who have beta thalassaemia major (an inherited blood disorder in which patients do not have enough normal haemoglobin in the blood) and who receive frequent blood transfusions;
u bolesnika u dobi od 6 godina i starijih koji imaju beta-talasemiju major (nasljedni poremećaj krvi pri kojemu bolesnici nemaju normalne vrijednosti hemoglobina u krvi) i koji često primaju transfuziju krvi;
Patients from birth to <2 months of age
Bolesnici od rođenja <2 mjeseca starosti
Patients from the age of 12 must take the contents of 1 jar with 75 mg.
Bolesnici stariji od 12 godina moraju uzeti sadržaj jedne posudice sa 75 mg.
Patients from the age of 2 years
Ispitanici stariji od 2 godine
Patients from the randomised trial were converted to perampanel over 16 weeks followed by a long term maintenance period (≥1 year).
Bolesnici iz randomiziranih ispitivanja bili su prebačeni na perampanel u roku od 16 tjedana, a potom je slijedilo dugo razdoblje održavanja (≥1 godine).
Patients from these trials were eligible to roll over into a blinded extension study.
Bolesnici iz tih ispitivanja bili su pogodni za prijelaz u slijepi produžetak ispitivanja.
Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25 % of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Tijekom dugotrajne izloženosti lijeku (najmanje 48 tjedana) povećanje tjelesne težine ≥ 7%, ≥ 15% i ≥ 25% od početne bilo je vrlo često (64,4%, 31,7%, odnosno 12,3%).
Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
U bolesnika koji su dugotrajno bili izloženi lijeku (najmanje 48 tjedana) porast tjelesne težine u odnosu na početnu vrijednost tjelesne težine za ≥ 7%, ≥ 5% odnosno ≥ 25% bio je vrlo čest (64,4%, 31,7% odnosno 12,3%).
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Tijekom dugotrajne izloženosti lijeku (najmanje 48 tjedana) povećanje tjelesne težine ≥ 7 %, ≥ 15 % i ≥ 25 % od početne bilo je vrlo često (64,4 %, 31,7 %, odnosno 12,3 %).
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Tijekom dugotrajne izloženosti lijeku (najmanje 48 tjedana), povećanje tjelesne težine ≥ 7 %, ≥ 15 % i ≥ 25 % od početne bilo je vrlo često (64,4 %, 31,7 %, odnosno 12,3 %).
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Tijekom dugotrajne izloženosti lijeku (najmanje 48 tjedana), povećanje tjelesne težine ≥ 7%, ≥ 15% i ≥ 25% od početne bilo je vrlo često (64,4%, 31,7%, odnosno 12,3%).
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term- exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Tijekom dugotrajne izloženosti lijeku (najmanje 48 tjedana), povećanje tjelesne težine ≥ 7%, ≥ 15% i ≥ 25% od početne bilo je vrlo često (64,4%, 31,7%, odnosno 12,3%).
Patients given only ipilimumab lived for only 2.9 months without their disease getting worse.
Bolesnici koji su primili samo ipilimumab živjeli su samo 2,9 mjeseci bez pogoršanja bolesti.
Patients given Opdivo survived for around 25.0 months, compared with 19.6 months in patients given everolimus.
Bolesnici koji su primili lijek Opdivo preživjeli su otprilike 25,0 mjeseci, u usporedbi s 19,6 mjeseci u bolesnika koji su primili everolimus.
Patients given the combination lived longer on average, 25.6 months versus 18 months with vemurafenib.
Bolesnici koji su primali kombinaciju lijekova živjeli su u prosjeku dulje, i to 25,6 mjeseci naspram 18 mjeseci koliko su živjeli bolesnici kojima je davan vemurafenib.
Patients given the combination lived longer on average, 25.6 months versus 18 months with vemurafenib.
Bolesnici koji su primali kombinaciju tih dvaju lijekova živjeli su u prosjeku dulje, 25,6 mjeseci naspram 18 mjeseci koliko su živjeli bolesnici kojima je davan vemurafenib.
Patients given the solution for infusion should be switched to Noxafil tablets or oral suspension as soon as the patient’s condition allows it.
Bolesnici koji primaju otopinu za infuziju trebaju je zamijeniti tabletama ili oralnom suspenzijom Noxafil čim njihovo stanje to dopusti.
Patients given Vectibix with FOLFIRI lived for an average of 14.8 months while patients given Vectibix with FOLFOX lived for an average of 12.8 months without their disease getting worse.
„FOLFOX” kemoterapijskim protokolom živjeli u prosjeku 12,8 mjeseci bez pogoršanja bolesti.
Patients given Xofigo also took longer for signs and symptoms of progressive disease such as fractures and bone pain to develop.
U bolesnika koji su primali Xofigo duže su se razvijali znakovi i simptomi progresivne bolesti, poput fraktura i boli u kostima.
Patients grouped under mutation types (n)
Bolesnici razvrstani u skupine prema tipu mutacije (n)
Patients had
American College of Rheumatology).
Patients had a blood eosinophil count of 150/L at baseline or a blood eosinophil count of 300/L in the 12 months prior to screening.
Bolesnici su imali početnu vrijednost eozinofila u krvi od  150 stanica/l ili vrijednost eozinofila u krvi od
Patients had a mean age of 42 years (range 19-73), 88% were male, 77% were White, 17% were Black, and 17% were Hispanic/Latino.
Srednja vrijednost dobi pacijenata bila je 42 godine (raspon 19-73), 88% bili su muškarci, 77% bijelci, 17% crnci, a 17% bili su hispanskog/latinoameričkog podrijetla.
Patients had a mean age of 42 years (range 19-73), 88% were male, 77% were White, and 17% were Black.
Bolesnici su imali srednju vrijednost dobi od 42 godinu (raspon 19-73), 88% su bili muškarci, 77% bijelci i 17% crnci.
Patients had a mean age of 5 years (range 6 months to 12 years) with 14 patients less than 2 years old and 6 patients one year or less.
Srednja dob bolesnika bila je 5 godina (raspon od 6 mjeseci do 12 godina), pri čemu je 14 bolesnika bilo mlađe od 2 godine, a njih 6 bilo je u dobi od jedne godine ili mlađe.
Patients had a median platelet count of 14 x 109/l at study entry.
Medijan broja trombocita pri uključenju bolesnika u ispitivanje bio je 14 x 109/l.
Patients had a median platelet count of 14 x 109/l at study entry.
Medijan broja trombocita pri uključivanju bolesnika u ispitivanje bio je 14 x 109/l.
Patients had a median platelet count of 19 x 109/l at study entry.
Medijan broja trombocita pri uključenju bolesnika u ispitivanje bio je 19 x 109/l.
Patients had ACS with moderate to high risk UA, NSTEMI, or STEMI and were managed with PCI.
ST-spojnice (NSTEMI) ili infarkta miokarda s elevacijom ST-spojnice (STEMI) i bili su podvrgnuti perkutanoj koronarnoj intervenciji (PCI).
Patients had active SLE disease, defined as a SELENA-SLEDAI (SELENA=Safety of Estrogens in Systemic Lupus Erythematosus National Assessment; SLEDAI=Systemic Lupus Erythematosus Disease Activity Index) score 6 and positive anti-nuclear antibody (ANA) test results (ANA titre 1:80 and/or a positive anti-dsDNA [30 units/ml]) at screening.
Bolesnici su imali aktivnu bolest, definiranu indeksom SELENA-SLEDAI (SELENA = Safety of Estrogens in Systemic Lupus Erythematosus National Assessment; SLEDAI = Systemic Lupus Erythematosus Disease Activity Index) 6 i pozitivan test na antinuklearna protutijela (ANA) - (ANA titar 1:80 i/ili pozitivna anti-dsDNK [30 jedinica/ml]) na probiru.
Patients had baseline HIV-1 isolates with a median of 16 HIV-1 protease gene mutations, including a median of 3 primary protease gene mutations D30N, L33F/I, V46I/L, G48V, I50V, V82A/F/T/L, I84V, and L90M.
Na početku studija, medijan broja mutacija u genu za proteazu iznosio je 16, a medijan broja primarnih mutacija gena za proteazu - D30N, L33F/I, V46I/L, G48V, I50V, V82A/F/T/L, I84V, i L90M - iznosio je 3.
Patients had been receiving opioid therapy for pain (median daily baseline oral morphine equivalent dose = 160 mg) and had opioid-induced constipation (<3 rescue medication-free bowel movements per week during the screening period).
Bolesnici su imali konstipaciju uzrokovanu opioidima (< 3 pražnjenja crijeva tjedno tijekom razdoblja probira bez primjene dodatnog laksativa).
Patients had clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions on the balding scalp or face within a contiguous 25 cm2 treatment area.
Bolesnici su imali klinički tipične, vidljive, diskretne, nehiperkeratotične i nehipertrofične lezije aktinične keratoze na tjemenu i licu u području liječenja veličine 25 cm2.
Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105 g/l, and a median platelet count of 221.5 x 109/l.
Bolesnici su imali mijelom IgG/IgA/lakih lanaca u 63%/25%/8% slučajeva, medijan hemoglobina od 105 g/l, i medijan broja trombocita od 221,5 x 109/l.